Huang Guo, member of the Party Leadership Committee and Deputy Director of the National Medical Products Administration, visited SUP on October 23rd afternoon. Huang Weijun, Secretary of the Party Leadership Committee and chief of the Fujian Provincial Drug Administration, Lin Changyuan, director of the Development Research Center of the Fujian Provincial People's Government, Fang Liangdong, Deputy Director of the Pingtan Comprehensive Experimental Zone Management Committee, Lin Donghong, Secretary of the Party Leadership Committee and Chairman of Fujian Pharmaceutical Group, and Wu Yaoquan, Secretary of the Party Leadership Committee and head of the Pingtan Comprehensive Experimental Zone Market Supervision Bureau, accompanied the visit and research.
Entering the corporate exhibition hall, the visiting delegation had a detailed understanding of the high-quality development process of SUP under the new policy of deepening the reform of the national drug review and approval system, which is “root on China to have a global vision”. They had in-depth communication and exchanges on the “Generic Drug cultivates innovation route and both types combined ”strategic positioning of the enterprise, as well as the layout of the industry chain, the internationalization process, the corporate culture and organizational construction.
Chief executive officer Li Wang introduced to the visiting delegation the innovative positioning and model of SUP, the joint planning of global introduction and self-developed products, the marketing situation of selected national centralized procurement drugs, the overview of approved products, and the progress of the evaluation of upcoming approved products. The visiting delegation fully affirmed the development achievements of SUP under the new policies of industry reform.
SUP has cooperated with more than 30 international enterprises, with a total of 22 approved products as 35 specifications. The R&D team has approved more than 30 chemical generic drugs and improved new drugs, including 17 formulations and 5 active pharmaceutical ingredients under development. As of now, 7 independently developed products are in the process of applying for registration.
On the Third Plenary Session of the 20th CPC Central Committee of the Communist Party of China, “Resolution of the Central Committee of the Communist Party of China on Further Deepening Reform Comprehensively to Advance Chinese Modernization”was adopted by the Session. It proposes to improve policies and governance systems for promoting the development of strategic industries such as biomedicine, focus on creating a globally competitive pharmaceutical innovation ecosystem, accelerate the pace of innovative drugs and medical devices being launched, improve the quality and efficiency of pharmaceutical industry development, and enhance the efficiency of review and approval. Chief executive officer Li Wang stated that SUP will closely follow the trend of national drugs regulatory reform and development, and contribute to the protection and promotion of public health and the Healthy China 2030 strategy by focusing on the overall plan of 100+products in 5 years.